Amarin Corp Plc (AMRN)

[IgnoranceIsBliss]

Well, at any rate, here's Cantor Fitzgerald's summary of the Epanova patent enfringement status:

We are keeping an eye on AZN's (NC) Epanova. In March 2014, AMRN filed a patent infringement suit against AZN, alleging infringement of AMRN's U.S. Patent No. 8,663,662 arising from the expected launch of Epanova. The patent covers methods of lowering triglycerides (TGs) by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than ~30% DHA. In November 2014, based on a representation from AZN that the commercial launch of Epanova was not imminent, the court dismissed AMRN's complaint, without prejudice, preserving AMRN's ability to later re-file the suit. AZN must notify AMRN before any product launch. We expect that if AZN notifies AMRN, AMRN will respond accordingly. Other patents covering Epanova include 9,918,955 and 10,016,386.